Literature DB >> 28296512

Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit.

F E Mellington1, C M Dayan2, A J Dickinson3, J L Hickey4, C J MacEwen5, J McLaren6, P Perros3, G E Rose1,7, J Uddin1,7, B Vaidya8, P Foley9, J H Lazarus9, A Mitchell9, D G Ezra1,7.   

Abstract

This article aims to provide baseline data and highlight any major deficiencies in the current level of care provided for adult patients with thyroid eye disease (TED). We undertook a prospective, nonrandomized cross-sectional multicenter observational study. During a 3-month period June-August 2014, consecutive adult patients with TED who presented to nominated specialist eye clinics in the United Kingdom, completed a standardized questionnaire. Main outcome measures were: demographics, time from diagnosis to referral to tertiary centre, time from referral to review in specialist eye clinic, management of thyroid dysfunction, radioiodine and provision of steroid prophylaxis, smoking, and TED classification. 91 patients (mean age 47.88 years) were included. Female-to-male ratio was 6:1. Mean time since first symptoms of TED = 27.92 (73.71) months; from first visit to any doctor with symptoms to diagnosis = 9.37 (26.03) months; from hyperthyroidism diagnosis to euthyroidism 12.45 (16.81) months. First, 13% had received radioiodine. All those with active TED received prophylactic steroids. Seven patients who received radioiodine and did not have TED at the time went on to develop it. Then, 60% patients were current or ex-smokers. 63% current smokers had been offered smoking cessation advice. 65% patients had active TED; 4% had sight-threatening TED. A large proportion of patients (54%) were unaware of their thyroid status. Not enough patients are being provided with smoking cessation advice and information on the impact of smoking on TED and control of thyroid function.

Entities:  

Keywords:  Amsterdam declaration; Thyroid eye disease; radioiodine; smoking; thyroid function

Mesh:

Substances:

Year:  2017        PMID: 28296512     DOI: 10.1080/01676830.2017.1280057

Source DB:  PubMed          Journal:  Orbit        ISSN: 0167-6830


  5 in total

Review 1.  Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.

Authors:  Faraat Ali; Anushma Chorsiya; Varisha Anjum; Asad Ali
Journal:  Int Ophthalmol       Date:  2021-01-22       Impact factor: 2.031

2.  A 'Real Life' Service Evaluation Model for Multidisciplinary Thyroid Eye Services.

Authors:  Soma Farag; Claire Feeney; Vickie Lee; Sonali Nagendran; Rajni Jain; Ahmad Aziz; Rashmi Akishar; Vassiliki Bravis; Karim Meeran
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-07       Impact factor: 5.555

3.  Association of Other Autoimmune Diseases With Thyroid Eye Disease.

Authors:  Mary Kelada; Parizad Avari; Soma Farag; Rashmi Akishar; Rajni Jain; Ahmad Aziz; Claire Feeney; Vassiliki Bravis; Karim Meeran; Vickie Lee
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-05       Impact factor: 5.555

Review 4.  Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review.

Authors:  Nickisa M Hodgson; Fatemeh Rajaii
Journal:  Ophthalmol Ther       Date:  2019-12-10

5.  Graves' Orbitopathy: Report of 82 cases.

Authors:  Samah Mbarek; Fatma Abid; Wafa Ammari; Wafa Alaya; Anis Mahmoud; Riadh Messaoud
Journal:  Tunis Med       Date:  2021-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.